Pharmaceuticals & Biotechnology
Valuation | |
|---|---|
| Market Cap | 21 kCr |
| Price/Earnings (Trailing) | 25.02 |
| Price/Sales (Trailing) | 8.17 |
| EV/EBITDA | 17.59 |
| Price/Free Cashflow | 38.42 |
| MarketCap/EBT | 18.87 |
| Enterprise Value | 20.8 kCr |
Fundamentals | |
|---|---|
Growth & Returns | |
|---|---|
| Price Change 1W | 0.60% |
| Price Change 1M | -6.9% |
| Price Change 6M | -8.1% |
| Price Change 1Y | 4% |
| 3Y Cumulative Return | 5.9% |
| 5Y Cumulative Return | 0.30% |
| 7Y Cumulative Return | 5.9% |
| 10Y Cumulative Return | 7.7% |
| Revenue (TTM) |
| 2.57 kCr |
| Rev. Growth (Yr) | 8.3% |
| Earnings (TTM) | 839.31 Cr |
| Earnings Growth (Yr) | 19.4% |
Profitability | |
|---|---|
| Operating Margin | 37% |
| EBT Margin | 43% |
| Return on Equity | 21.81% |
| Return on Assets | 18.22% |
| Free Cashflow Yield | 2.6% |
Cash Flow & Liquidity |
|---|
| Cash Flow from Investing (TTM) | -71.34 Cr |
| Cash Flow from Operations (TTM) | 659.75 Cr |
| Cash Flow from Financing (TTM) | -205.34 Cr |
| Cash & Equivalents | 205.35 Cr |
| Free Cash Flow (TTM) | 631.6 Cr |
| Free Cash Flow/Share (TTM) | 138.06 |
Balance Sheet | |
|---|---|
| Total Assets | 4.61 kCr |
| Total Liabilities | 757.23 Cr |
| Shareholder Equity | 3.85 kCr |
| Current Assets | 3.48 kCr |
| Current Liabilities | 645.65 Cr |
| Net PPE | 154.63 Cr |
| Inventory | 500.47 Cr |
| Goodwill | 527.49 Cr |
Capital Structure & Leverage | |
|---|---|
| Debt Ratio | 0.00 |
| Debt/Equity | 0.00 |
| Interest Coverage | 115.19 |
| Interest/Cashflow Ops | 70.08 |
Dividend & Shareholder Returns | |
|---|---|
| Dividend/Share (TTM) | 200 |
| Dividend Yield | 4.36% |
| Shares Dilution (1Y) | 0.00% |
| Shares Dilution (3Y) | 0.00% |
Dividend: Pays a strong dividend yield of 4.36%.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 33%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: In past three years, the stock has provided 5.9% return compared to 13.2% by NIFTY 50.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock has a weak negative price momentum.
Dividend: Pays a strong dividend yield of 4.36%.
Balance Sheet: Strong Balance Sheet.
Profitability: Very strong Profitability. One year profit margin are 33%.
Size: Market Cap wise it is among the top 20% companies of india.
Buy Backs: Company has bought back it's stock in the past which is a good thing.
Smart Money: Smart money has been increasing their position in the stock.
Past Returns: In past three years, the stock has provided 5.9% return compared to 13.2% by NIFTY 50.
Technicals: SharesGuru indicator is Bearish.
Momentum: Stock has a weak negative price momentum.
Investor Care | |
|---|---|
| Dividend Yield | 4.36% |
| Dividend/Share (TTM) | 200 |
| Shares Dilution (1Y) | 0.00% |
| Earnings/Share (TTM) | 183.47 |
Financial Health | |
|---|---|
| Current Ratio | 5.38 |
| Debt/Equity | 0.00 |
Technical Indicators | |
|---|---|
| RSI (14d) | 41.59 |
| RSI (5d) | 53.73 |
| RSI (21d) | 37.58 |
| MACD Signal | Buy |
| Stochastic Oscillator Signal | Hold |
| SharesGuru Signal | Sell |
| RSI Signal | Hold |
| RSI5 Signal | Hold |
| RSI21 Signal | Hold |
| SMA 5 Signal | Sell |
| SMA 10 Signal |
Summary of Pfizer's latest earnings call, featuring management's outlook on business performance, financial results, and analyst Q&A sessions that highlight key strategic initiatives and market challenges.
Understand Pfizer ownership landscape with insights into key distribution patterns, offering investors a clear view of stakeholder dynamics.
| Shareholder Name | Holding % |
|---|---|
| PFIZER EAST INDIA B V | 39.75% |
| WYETH LLC | 12.28% |
| NIPPON LIFE INDIA TRUSTEE LTD | 4.17% |
| WYETH HOLDINGS CORPORATION | 3.56% |
| WARNER-LAMBERT COMPANY LLC | 2.6% |
| QUANT MUTUAL FUND | 2.22% |
| ICICI PRUDENTIAL FUND | 2.12% |
Detailed comparison of Pfizer against industry peers, highlighting key financial metrics, valuation ratios, and performance indicators to provide competitive context within the sector.
Ticker | Name | Mkt Cap | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|
Comprehensive comparison against sector averages
PFIZER metrics compared to Pharmaceuticals
| Category | PFIZER | Pharmaceuticals |
|---|---|---|
| PE | 25.02 | 33.54 |
| PS | 8.17 | 4.66 |
| Growth | 5.7 % | 9.1 % |
Pfizer Limited engages in manufacturing, marketing, trading, and export of pharmaceutical products in India and internationally. It offers its products in various therapeutic areas, including neuro/CNS, hormones, cardiovascular, haemophilia, anti-infectives, gynecology, pain/analgesics, orthopedic, oncology, urology, anti-parasitic, gastro intestinal, vaccines, and respiratory, as well as vitamins, minerals, and nutrients. The company also offers internal medicine and anti-infectives services to hospitals and nursing homes. It serves healthcare providers, government and private hospitals, and retail pharmacies. The company sells its products through a network of independent distributors. Pfizer Limited was incorporated in 1950 and is based in Mumbai, India.
This is an informational page just to provide a quick 'first look' at the stock. You must do your own deeper research. Know your risk appetite. Consult a SEBI-registered financial advisor before making any investment decisions.
| Sell |
| SMA 20 Signal | Sell |
| SMA 50 Signal | Sell |
| SMA 100 Signal | Sell |
PFIZER vs Pharmaceuticals (2021 - 2026)
| ATUL LIMITED | 2.1% |
| PARKE, DAVIS & COMPANY LLC | 2.09% |
| JOHN WYETH & BROTHER LTD | 1.93% |
| PHARMACIA CORPORATION | 1.71% |
| FOREIGN BANK | 0% |
Distribution across major stakeholders
Distribution across major institutional holders
| 408 |
| 416 |
| 402 |
| 378 |
| 408 |
| Profit Before exceptional items and Tax | 51.5% | 260 | 172 | 215 | 203 | 244 | 168 |
| Exceptional items before tax | - | 0 | 0 | 0 | 0 | 0 | 7.95 |
| Total profit before tax | 51.5% | 260 | 172 | 215 | 203 | 244 | 176 |
| Current tax | 34.7% | 67 | 50 | 60 | 55 | 49 | 29 |
| Deferred tax | 90.3% | 0.39 | -5.26 | -3.01 | -3.14 | 16 | 17 |
| Total tax | 52.3% | 68 | 45 | 57 | 52 | 65 | 46 |
| Total profit (loss) for period | 50.4% | 192 | 128 | 158 | 151 | 179 | 130 |
| Other comp. income net of taxes | -24.7% | -0.92 | -0.54 | -0.53 | -0.54 | 7.93 | -0.83 |
| Total Comprehensive Income | 50.8% | 191 | 127 | 158 | 150 | 187 | 129 |
| Earnings Per Share, Basic | 52.1% | 41.91 | 27.89 | 34.61 | 32.94 | 22.33 | 27.12 |
| Earnings Per Share, Diluted | 52.1% | 41.91 | 27.89 | 0 | 32.94 | 22.33 | 27.12 |